Get Thin MD review

Get Thin MD publishes a $199 month-to-month NAD⁺ offer and $129 monthly equivalent on a twelve-month product page, while its homepage ties $129 to three months. That conflict prevents a reliable $129 floor. Sermorelin still has a $129 entry headline without a confirmed plan ladder, and the current page chiefly describes an injection. The FAQ names four pharmacy partners, though none is assigned to a specific order. Its cancellation sources disagree at 72 and 36 hours.

Get Thin MD Inc is an asynchronous telehealth brand with Robert G. Darling named as chief medical officer. Its wellness lines include sermorelin injection and NAD⁺ injection or nasal spray, alongside GLP-1, hormone, hair and biomarker programs. Sermorelin navigation also advertises an oral option, but the current treatment page focuses on subcutaneous injection and does not define an oral formulation or quantity. The FAQ names Triad Rx, Precision Medicine, Red Rock and Beaker as pharmacy partners; patient-specific assignment and prescribing group are not disclosed. The brand claims nationwide access without a product-state map.

An online evaluation precedes provider review and conditional prescription, with delivery from a pharmacy partner. The sermorelin page says labs may be ordered; the separate biomarker program is not automatically included. The fulfillment policy calls for cancellation email at least 72 hours before billing, while terms describe call, email or missed refill questionnaire taking effect in 36 hours. They also differ on initial payment timing and medical-ineligibility refund amount. Ordered medication is generally nonreturnable, with documented damage or error handled separately. Its four-month weight-loss guarantee applies to qualifying GLP-1 treatment after sixteen weekly doses, with a less-than-ten-percent-loss condition and other eligibility requirements; it does not cover sermorelin or NAD⁺.

NAD⁺ injection or nasal-spray care is advertised at $199 a month month to month or $129 monthly equivalent on a twelve-month product-page option. The homepage describes $129 with a three-month plan instead. Neither page establishes the selected longer-plan debit, route-specific price or dispensed quantity. Sermorelin retains a $129 entry headline without a confirmed month-to-month ladder or universal three-month commitment. Separate GLP-1 offers list semaglutide at $169 monthly equivalent on three months paid upfront or financed, $199 monthly, and tirzepatide at $299 monthly. The GLP-1 same-dose pricing promise does not automatically apply to wellness products.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Get Thin MD publishes the disclaimer verbatim — its own copy states the FDA does not review or approve any compounded medications for safety or effectiveness — and its sermorelin page states that sermorelin is available only as a compounded medication prepared by licensed compounding pharmacies, not as an FDA-approved drug product. It names Triad Rx, Precision Medicine, Red Rock and Beaker as pharmacy partners without assigning one to the patient, and compounded sterile products are not FDA-reviewed for purity and potency the way approved drugs are. On the evidence, the two wellness lines are not equivalent and the site does not distinguish between them. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism, but the long-term human outcome data stays thin and no controlled trial demonstrates the muscle-growth results the line is marketed under; an oral route mentioned in navigation has no defined formulation or comparative bioavailability data published on the site. Injected and intranasal NAD⁺ have no controlled human outcome trials at all; the NAD⁺ forms with human data are the oral precursors NR and NMN, and what they demonstrate is a raised blood NAD⁺ level rather than an improved outcome. Individual results vary.